The Wilms tumor gene (WT1) encodes a zinc-finger containing transcription factor present in primitive hematopoietic progenitor cells. WT1 is also highly expressed in most cases of acute myeloid leukemia. Moreover, WT1 can interfere with induced differentiation of leukemic cell lines. These data suggest a function of WT1 in the maintenance of a primitive phenotype and a role in leukemogenesis by interfering with differentiation, prompting us to investigate its function in human hematopoietic progenitor cells. By retroviral transfer, human CD34
Introduction
The Wilms tumor gene (WT1) was originally characterized as a tumor suppressor gene, mutations of which contribute to the initiation of childhood nephroblastoma (Wilms tumor). [1] [2] [3] Targeted deletion of WT1 in mice results in a lethal phenotype with absence of gonads, liver and spleen, as well as defective development of heart and mesenchymal structures 4, 5 demonstrating the importance of WT1 for the development of these tissues.
WT1 encodes a protein with the characteristics of a transcription factor; four carboxyl terminal zinc-fingers with high homology to the zinc-fingers of the Egr-1 transcription factor form a DNA-binding domain, and a proline-glutamine rich region that is capable of regulating transcription (reviewed in Refs 6 and 7). A few endogenous genes have been demonstrated to be physiologically regulated by WT1, among them the genes encoding the epidermal growth factor receptor, syndecan 1, bcl-2, amphiregulin and E-cadherin. [8] [9] [10] [11] Alternative splicing of the WT1 transcript results in the presence or absence of 17 amino acids just upstream of the zinc-fingers (±17AA). A second alternative splicing includes or excludes a 3-amino acid (lysine-threonine-serine) insert between zinc fingers 3 and 4 (±KTS). 12 
WT1 is normally expressed in CD34
+ hematopoietic progenitor cells 13, 14 and disappears during the differentiation of these cells in vitro. 15 WT1 is not detectable in peripheral mature blood cells.
14 WT1 is strongly expressed in leukemic cells from the majority of human acute leukemias and in blast crisis of chronic myeloid leukemia. 13, 16, 17 Moreover, the expression of WT1 is weaker in the more differentiated AMLs of M4 and M5 subtype. 18 It is not clear whether WT1 is indeed over-expressed in leukemic blasts, as compared to normal hematopoietic progenitors, 13, 15, 17, 19 but one comprehensive study concluded that the WT1 levels in leukemic cells are higher than those of any comparable normal bone marrow or cord blood cell, 20 suggesting involvement of WT1 in leukemogenesis. WT1 has been considered to be a prognostic marker in acute leukemia 17, 21, 22 and immunization with WT1 peptides can raise a cytotoxic response to tumor cells in vitro and in vivo. [23] [24] [25] In addition, WT1 mutations, most commonly heterozygous, occur in approximately 15% of AML cases and are associated with a poor response to chemotherapy. [23] [24] [25] [26] [27] Induction of differentiation of some leukemic cell lines is associated with a rapid decrease of WT1 28, 29 and over-expression of WT1 in several myeloid cell lines was found to interfere with the induced differentiation of these cells. 18, [30] [31] [32] [33] Thus, it is possible that WT1 has a role in hematopoietic differentiation. Moreover, murine bone marrow cells transduced with human WT1 showed an increased capacity for granulocyte colonystimulating factor (G-CSF)-induced colony formation. In addition, WT1 expressing cells showed an impaired differentiation. 34 Taken together, these data suggest that WT1 could have a role in leukemogenesis by blocking cell differentiation. Thus, WT1 may normally be involved in the preservation of the phenotype of early progenitor cells, counteracting proliferation and differentiation along the different maturation lineages. Increased knowledge on the function of WT1 should be important for our understanding of its role in hematopoiesis and leukemogenesis.
The aim of this work was to investigate the functional role of WT1 for proliferation and differentiation of human hematopoietic progenitor cells. To this end, retroviral transfer of WT1 cDNA was utilized to achieve a forced expression of human WT1 in CD34
+ cord blood cells. Our results show that WT1 confers an anti-proliferative effect and an inhibition of in vitro colony formation while no impairment of the maturation of the cells was detected.
Materials and methods

Preparation of human CD34
+ cells from cord blood
Umbilical cord blood samples were, after informed consent, collected at the Department of Obstetrics and Gynecology, Malmö University Hospital from mothers giving birth to nor-mal, full-term infants. Samples were stored for less than 24 h at 4°C in DMEM (Gibco BRL, Paisley, UK), 0.1% detoxified bovine serum albumin (BSA) (StemCell Technologies, Vancouver, Canada), heparin at 150 IU/ml (Pharmacia, Stockholm, Sweden), 100 IU/ml penicillin, and 100 g/ml streptomycin (Gibco BRL). Mononuclear cell isolation was performed using Lymphoprep (Nycomed, Oslo, Norway) according to the manufacturer's instructions. CD34 + cell enrichment was performed using Midi MACS LS+ separation columns and cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) as per the manufacturer's instructions. CD34 + cell purity was 90-95% as determined by flow cytometric analysis. The cells were frozen and stored in liquid nitrogen before use.
Retroviral vectors
Three retroviral vectors were constructed by inserting different expression cassettes into the MSCV vector, which is based on the murine stem cell virus. 35 A control vector designated MIG was constructed by insertion of an internal ribosomal entry site (IRES) from the encephalomyocarditis virus 36 linked to an expression cassette for the gene for enhanced green fluorescent protein (GFP). cDNA fragments for two different isoforms of WT1, including the 17 amino acid insert and the KTS insert (WT1(+/+)) and the 17 amino acid insert only (WT1(+/−)), were created by PCR amplification of the cDNA for human WT1 (generously provided by Dr F Rauscher III, The Wistar Institute, Philadelphia, PA, USA). This allowed the inclusion of restriction enzyme sites for subsequent cloning into the MIG vector upstream of the IRES and generation of the two retroviral vectors MWIG(+/+) (containing WT1(+/+)) and MWIG(+/−) (containing WT1(+/-)), respectively. The integrity of the reading frames was verified by DNA sequencing.
Generation of producer cell lines
The Phoenix ampho packaging cell line (generously provided by Dr Garry P Nolan, Stanford University School of Medicine, Stanford, CA, USA) was cultured in DMEM with 10% FCS (Gibco BRL) and penicillin/streptomycin and transfected with the three different vectors using CaPO 4 precipitation under standard conditions. After 24-48 h, supernatants were harvested and filtered through a 0.45 m low-protein binding filter (Millipore, Bedford, MA, USA). Supernatants were then supplemented with protamine sulfate (Sigma Chemicals, St Louis, MO, USA) at a final concentration of 4 g/ml and used for repeated transduction of 293-GPG cells, generously provided by Dr Richard Mulligan, Children's Hospital, Boston, MA, USA. 37 In the 293-GPG packaging cell line the production of the vesicular stomatitis virus G envelope protein is repressed in the presence of tetracycline. When almost confluent, tetracycline-containing medium was changed to DMEM with 10% FCS and penicillin/streptomycin. Forty-eight hours after tetracycline removal, medium was replaced with new tetracycline-free medium which was harvested 24 h later, filtered and stored at −80°C. New harvests were performed every 24 h up to 144 h. The titer of each individual batch of virus-containing medium was assessed by transduction of NIH3T3 cells and subsequent determination of the proportion of GFP-positive cells by FACS analysis 48 h later. Titers of the supernatants used in all subsequent experiments were 10 6 -10 7 infectious units/ml. −4 m 2-mercaptoethanol, 2 mm l-glutamine (Gibco BRL), 50 U/ml penicillin/streptomycin, 100 ng/ml thrombopoietin (TPO), 100 ng/ml stem cell factor (SCF) and 100 ng/ml Flt3-ligand 38, 39 (all recombinant human cytokines were obtained from StemCell Technologies). After pre-stimulation, cells were further cultured for 48 h at a density of 5 × 10 4 cells/ml in viral supernatant supplemented with 100 ng/ml TPO, 100 ng/ml SCF and 100 ng/ml Flt3-ligand, in Retronectin-coated (Takara, Otsu, Shiga, Japan) non-tissue culture-treated 24-well plates. The wells were coated with Retronectin according to the manufacturer's instructions, blocked with 2% BSA in PBS for 30 min at room temperature and pre-coated with viral supernatant for 60 min at 37°C before cells were added. After the 48 h transduction period, cells were washed once in DMEM with 10% FCS and then subjected to flow cytometric analysis for GFP expression and sorting.
Flow cytometric sorting of GFP-expressing cells
GFP-expressing cells were purified using a FACS Vantage Cell Sorter (Becton Dickinson Immunocytometry System, San José, CA, USA) upgraded with a Turbo Sort unit and equipped with a 488 nm argon laser. Single, viable and GFP-expressing cells were selected by gating based on the laser scatter profile and fluorescence at 515-545 nm. The cells were sorted at a rate of 2000-4000 cells per second.
Cultures of WT1-transduced human hematopoietic progenitor cells
Analysis of clonogenic growth of transduced cells that expressed GFP was performed immediately after FACS sorting by suspending the cells (1000 cells/ml) in methylcellulose medium containing the following recombinant human cytokines: SCF (50 ng/ml), GM-CSF (10 ng/ml), IL-3 (10 ng/ml), erythropoietin (EPO) (3 U/ml) (MethoCult No. H4434; StemCell Technologies). Cells were subsequently plated into 35 mm dishes in triplicates. Myeloid (CFU-GM, CFU-G and CFU-M) and erythroid (BFU-E) colonies were counted after 14 days of culture.
Transduced and FACS sorted cells were also grown in liquid culture at an initial density of 5 × 10 4 cells/ml in IMDM supplemented with 30% FCS, 1% bovine serum albumin, 10 −4 m 2-mercaptoethanol, 2 mm l-glutamine, 50 U/ml penicillin/streptomycin, 50 ng/ml SCF, 10 ng/ml IL-3 (both recombinant human cytokines from StemCell Technologies), 10 ng/ml GM-CSF (Leucomax; Schering-Plough, Kenilworth, NJ, USA) and 3 U/ml EPO (Eprex; Janssen-Cilag, Sollentuna, Sweden). The medium was replaced twice with fresh medium, including supplements during the 14 day culture period and at the same time the cells were diluted to a density of 2 × 10 5 cells/ml. Cells were counted daily in a Bü rker chamber and the viability was determined by trypan blue exclusion.
Briefly, cells were washed in PBS and incubated at room temperature in the dark for 60 min in a nuclear isolation medium containing propidium iodide (50 g/ml propidium iodide, 0.6% Nonident P40, 100 g/ml RNase (DNase-free) in PBS; all reagents from Sigma). Cells were then analyzed in a FACScan flow cytometer (Becton Dickinson). Up to 10 000 nuclei were analyzed per sample. Using the electronic peak and area detectors, processor signals from nuclei doublets were rejected. Cell cycle phase distribution, ie the percentages of G0-G1, S and G2 nuclei of the analyzed cell population, was determined by applying ModFit LT cell cycle analysis software (Verity Software House, Topsham, ME, USA) on the DNA histogram. The DNA histogram was corrected for contribution of nucleic debris.
Flow cytometric analysis
Expression of GFP was analyzed using a FACScan flow cytometer (Becton Dickinson). Different cell surface markers were analyzed by FACS as described previously. 30 Briefly, cells were washed in PBS and resuspended to 1-5 × 10 6 cells/ml. Fifty l of the cell suspension was incubated for 10 min at room temperature under constant agitation with the following antibodies: control IgG1-FITC/IgG1-PE, CD34-PE, CD14-PE (all Becton Dickinson), CD11b-PE and GPA-PE (both Dako, Copenhagen, Denmark). The cells were then washed three times and fixed in 1% paraformaldehyde before flow cytometric analysis.
Western blot analysis
Western blot analysis was performed as described previously. 40 Briefly, 1 × 10 6 cells were washed once with PBS and cell lysates were prepared by lysis through sonication in 60 l lysis buffer (85 mm Tris-HCl, pH 6.8, 2.2% SDS, 10% glycerol, 160 mm 2-mercaptoethanol, 2.5% bromophenol blue). Cell lysates were then boiled for 5 min, and subsequently centrifuged at 14 000 g for 5 min. Lysates corresponding to 0.2-0.3 × 10 6 cells were loaded in each well of a precast 10-20% Tris-Glycine gel (Novex, San Diego, CA, USA). After electrophoresis, the proteins were transferred to a Hybond-P PVDF membrane (Amersham Life Science, Amersham, UK), which was probed with a polyclonal rabbit antibody against WT1 (C-19; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The protein expression was then detected by using the ECL-Plus Western blotting analysis system (Amersham Life Science) according to the manufacturer's instructions.
RNA preparation and RT-PCR analysis
Total RNA was obtained from 0.5-1 × 10 6 cells using the QIAprep Miniprep Kit (Qiagen, Valencia, CA, USA). Two hundred and fifty ng RNA was reverse-transcribed by using Omniscript Reverse Transcriptase Kit (Qiagen) and an oligo dT primer according to the manufacturer's instructions. Subsequent PCR reactions were performed with 4 l of the reverse transcription reaction in a 50 l volume. WT1-transcript (exons 1-10) was amplified using the forward 5′-GACTTCGGATTCAAGCTTG CCACCATGGGTTCCGACGTTCGTGAC-3′ and reverse 5′-GACTTCGATATCGTGCACTCTAGATCAAAGCGCCAGCTGG AGTTT-3′ primers for 25 cycles (denaturation 95°C, 45 s; annealing 55°C, 45 s; extension 72°C, 3 min). For the detection of ␤-actin the forward 5′-GAGCAAGAGAGGCAT CCTCACCC-3′ and reverse 5′-CCAGCCAGGTCCAGACGC AGG-3′ primers were used for 23 cycles (denaturation 95°C, 30 s; annealing and extension 60°C, 40 s). The PCR products were analyzed on 1% agarose gels. Cell-and reverse transcriptase-free samples were used as negative controls.
Preparation, transduction and clonal analysis of murine hematopoietic progenitor cells
Murine bone marrow cells were harvested from B6/SJL mice by flushing the femoral bones with 5 ml of culture medium and washing the cells once in DMEM with 15% FCS. The bone marrow cells were pre-stimulated for 48 h in DMEM, containing 15% FCS, 10 ng/ml recombinant mouse IL-3, 50 ng/ml recombinant rat SCF (generous gifts from Genetics Institute, Cambridge, MA, USA) and 50 ng/ml recombinant human IL-6 (StemCell Technologies). After pre-stimulation, cells were cultured at a density of 0.3 × 10 6 cells/ml in a viruscontaining supernatant, supplemented with 10 ng/ml IL-3, 50 ng/ml SCF and 50 ng/ml IL-6, in Retronectin-coated nontissue culture-treated 6-well plates, as described above. After 48 h, GFP-expressing cells were isolated by flow cytometry sorting and plated in methylcellulose medium (MethoCult No. M3434, StemCell Technologies). CFU-GM were counted after 7 days of culture.
Statistical analysis
Student's t-test was used for statistical analysis.
Results
Retroviral vectors for expression of WT1
Murine stem cell virus (MSCV)-based retroviral vectors were used in this study to establish constitutive expression of the two different isoforms of WT1; WT1(+/+) and WT1(+/-), in human and murine hematopoietic progenitor cells. The retroviral vectors MWIG(+/+) and MWIG(+/-) contained the cDNA for WT1(+/+) and WT1(+/−), respectively, together with GFP cDNA. As a result of an internal ribosomal entry site (IRES), the LTR promoter drove the expression of a bicistronic mRNA encoding both WT1 and GFP (Figure 1 ). The control vector Figure 1 Schematic picture of the retroviral vectors MIG, MWIG(+/+) and MWIG(+/−). As a result of an internal ribosomal entry site (IRES), the LTR promoter drives the expression of a bicistronic mRNA encoding both WT1 and GFP.
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Transduction efficiency of human CD34
+ cells with retroviral vectors expressing WT1
CD34
+ cells were isolated from cord blood to a purity of 90-95% and pre-stimulated into cell division by incubating them for 48 h in serum-free medium with the cytokines TPO, SCF and Flt3-ligand. After infection by incubation for an additional 48 h with viral supernatants as described in Methods, the transduction efficiency was determined by analysis of GFP and CD34 expression using flow cytometric analysis. The mean transduction efficiencies were 33% (MIG), 16% (MWIG(+/+)) and 20% (MWIG(+/−)) ( Table 1 ). More than 80% of the GFP + cells of all three populations retained expression of CD34, indicating a similar preservation of an immature phenotype under the transduction conditions described (Table 1) . Therefore, all cells expressing GFP were isolated by After the 48 h transduction period, the efficiency of transduction was determined by analysis of GFP expression using flow cytometric analysis. In addition, the expression of CD34 was determined. Mean values ± s.e.m. from at least four independent experiments are shown.
Leukemia flow cytometric cell sorting using the R2 gate shown in Figure 3 for subsequent in vitro culture.
Cloning efficiency of WT1-transduced human hematopoietic progenitor cells
To evaluate the effect of WT1 expression on the colonyforming capacity of human hematopoietic progenitors, the sorted GFP-positive cells transduced with the MIG, MWIG(+/+) or MWIG(+/−) vectors were cultured in methylcellulose medium supplemented with multiple cytokines, supporting both myeloid and erythroid differentiation. MIG-transduced control cells generated 32 ± 4 (s.e.m.) myeloid (CFU-GM, CFU-G and CFU-M) and 36 ± 6 (s.e.m.) erythroid (BFU-E) colonies per 1000 plated cells after 14 days of culture ( Figure 4) . However, cells expressing WT1 showed a significantly reduced capacity to form both myeloid and erythroid colonies compared to MIG transduced cells (Figure 4 ). Interestingly, this effect was significantly stronger with WT1(+/−) compared to WT1(+/+) on myeloid colony formation, while no difference between the two isoforms was detected with respect to inhibition of erythroid colony formation. In addition, the WT1-expressing colonies were slightly smaller in size, especially BFU-E, when compared to colonies formed by MIG-transduced cells (data not shown). The differences observed in colony number and size between MIG and MWIG-transduced cells remained after 21 days in culture (data not shown). We conclude that enforced expression of WT1 in human hematopoietic progenitors reduced the capacity to form myeloid and erythroid colonies. 
Analysis of proliferation, cell cycle phase distribution and viability of WT1-transduced cells
To investigate the mechanism behind the reduced capacity of WT1-transduced cells to form colonies we studied the effects of WT1 on proliferation, cell cycle phase distribution and survival in liquid culture. Cells transduced with MWIG(+/+) or MWIG(+/−) showed a reduced proliferation rate during the first days of culture as compared to MIG transduced control cells ( Figure 5 ). No significant difference in cell cycle distribution was detected between MIG and WT1-transduced cells 4 cells/ml were grown in liquid culture as described in Methods. The total number of cells and the viability, as judged by trypan blue exclusion, were determined daily. Results from one representative experiment out of three performed are shown. Viability was always more than 90% throughout the experiment.
( Figure 6 ). A small increase of cells in the G2/M phase could be noted, but this did not reach statistical significance. WT1 transduced cells did not show any signs of toxicity as compared to MIG-transduced cells, neither during the transduction nor during the liquid culture period. The viability, as judged by trypan blue exclusion, was similar for MIG and WT1-transduced cells and always more than 90% (data not shown). Furthermore, the proportion of dead cells that could be identified in the sub-G1 phase in the cell cycle analysis did not differ significantly between WT1 and MIG-transduced cells. Thus, human hematopoietic progenitors transduced with either of the isoforms of WT1, WT1(+/+) or WT1(+/−), showed growth inhibition during the first days in liquid culture. However, this growth inhibition could not be correlated to detectable effects on the cell cycle or viability of WT1-transduced cells.
Differentiation of WT1-transduced cells
We and others have reported that WT1 can interfere with differentiation of hematopoietic cells. 18, [30] [31] [32] 41 The effect of WT1 on the differentiation of human hematopoietic progenitors cells was therefore evaluated. For this purpose the expression of the myeloid markers CD14 and CD11b and the erythroid marker glycophorin A (GPA) was analyzed by flow cytometry. Prior to culture, freshly isolated CD34
+ cells showed CD14 expression in 1%, CD11b expression in 7% and GPA expression in 0% of the cells (data not shown). Sorted GFPexpressing cells infected with MIG, MWIG(+/+) and MWIG(+/−) vectors were grown in a liquid culture, with the medium composition as described in Materials and methods. These culture conditions promote both myeloid and erythroid differentiation. After 14 days of culture, MIG-transduced cells grown in a liquid culture up-regulated CD14, CD11b and GPA as expected. CD34 expression was not detectable at this time (data not shown). As shown in Table 2 , the frequency of MWIG(+/+) or MWIG(+/−)-transduced cells expressing either of the differentiation markers after 14 days of culture was not different from MIG-transduced control cells. These results demonstrate that a forced expression of WT1 in human hematopoietic progenitors is compatible with induced myeloid and erythroid differentiation as judged by expression of the surface markers CD11b, CD14 and GPA.
Expression of transduced WT1 protein and transcript
We then evaluated the level of enforced WT1 expression in the transduced and sorted cells. To measure the level of WT1 protein, cells were collected from the liquid culture on day 7 and analyzed by Western blotting. As shown in Figure 7a , a higher level of WT1 protein was detected in MWIG(+/+) and MWIG(+/−)-transduced cells compared to the low or undetectable levels of endogenous WT1 protein observed in control or MIG-transduced cells. WT1 transcripts in transduced cells were also analyzed immediately after FACS sorting by using a RT-PCR assay. WT1 transcripts were detected in MWIG(+/+) and MWIG(+/−)-transduced cells but not in control cells transduced with the MIG vector only (Figure 7b) , which is in accordance with protein expression data.
Cloning efficiency of WT1-transduced murine progenitor cells
We also studied the effect of an enforced expression of two different isoforms of WT1; WT1(+/+) and WT1(+/−), on the
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Figure 6
WT1 does not affect cell cycle distribution of CD34 + human cells. Sorted GFP-positive cells transduced with the MIG, MWIG(+/+) or MWIG(+/−) retroviral vectors were cultured in liquid culture for 1 day and the cell cycle distribution was analyzed by flow cytometry as described in Methods. One representative experiment out of three is shown.
Table 2
Expression of differentiation markers on transduced hematopoietic progenitor cells % CD14 % CD11b % GPA colony-forming capacity of murine progenitor cells. It has recently been reported that constitutive expression of the isoform of human WT1(+/+) in murine hematopoietic progenitor cells promotes proliferation during culture with G-CSF only.
34
Sorted GFP-positive cells transduced with the MIG, MWIG(+/+) or MWIG(+/−) vectors were cultured in methylcellulose medium, supplemented with SCF, IL-3, IL-6 and EPO, supporting both myeloid and erythroid differentiation. After 7 days of culture colonies were counted. Cells expressing WT1 showed a slightly reduced, but not statistically significant, capacity to form CFU-GM as compared to MIG-transduced cells (Figure 8 ). Too few BFU-E and CFU-GEMM were detected in the methylcellulose cultures for a valid comparison. There was no difference in size between CFU-GM generated by MIG and MWIG(+/+) or MWIG(+/−)-transduced cells (data not shown). Our observations are consistent with Tsuboi et al, 34 who demonstrated, using multiple cytokines, that there were no significant effects of human WT1 on clonogenic growth of murine hematopoietic progenitor cells.
Discussion
The present results demonstrate that a forced expression of WT1 in hematopoietic progenitors confers an inhibition of colony formation in vitro and a retarded proliferation in liquid culture. We also show that WT1 expression is compatible with maturation along myeloid and erythroid lineages.
By employing retroviral transfer of bicistronic vectors encoding WT1 and GFP to cord blood progenitor cells, 16 cannot be ruled out that a minority of control cells express WT1 to a level comparable to that of transduced cells.
The majority of the CD34 + cells retained CD34 expression after the completed transduction procedure. This showed that there were no major differences between the control and WT1-transduced cells, indicating a preserved immature phenotype that was not affected by WT1 expression during the course of transduction. The mean transduction efficiency with vectors containing WT1 was slightly lower than that with control virus (Table 1) . We observed a marked reduction in colony-forming capacity of WT1-transduced cells, which could not be explained by lower transduction efficiency of the WT1-expressing vectors, since separate experiments with identical transduction efficiency for all three vectors also showed reduction in colony formation from WT1-transduced cells. Very recently, Ellisen et al 41 showed that WT1 expression resulted in reduced proliferation of human early hematopoietic progenitor cells, consistent with our data. However, our results also indicate that WT1(+/+) showed a stronger inhibitory effect on erythroid colony formation, as compared to myeloid colony formation, while WT1 (+/−) reduced the number of erythroid and myeloid colonies to a similar degree. This could represent a true functional difference between WT1 with or without the KTS insertion, and suggests that WT1 may be involved in lineage choice in hematopoiesis.
The observed retarded proliferation of WT1-expressing cells in suspension culture is consistent with the reduction of the clonogenic growth. However, it is conceivable that, at least partly, non-identical cells are responsible for the observed reduced proliferation in suspension and clonogenic growth assays. Therefore, the anti-proliferative effect of WT1 does not seem to be restricted to clonogenic progenitors. Growth arrest of cells commonly occurs in the G1 phase of the cell cycle but analysis of the cell cycle distribution revealed no significant difference between control cells and WT1-transduced cells. This is in contrast to some cell lines showing WT1-induced G1 arrest. [41] [42] [43] [44] It should be noted however, that while only a fraction of the cells are responsible for the observed growth (in particular in clonogenic assays), the cell cycle analysis is performed on the total cell population. Therefore, selective effects on the cell cycle regulation in cells with clonogenic/proliferative capacity cannot be excluded.
Our results show no sign of any toxic effects of WT1, as judged by viability and appearance of the sub-G1 peak in the cell cycle analysis, supporting that the present growth inhibitory effects of WT1 are due to anti-proliferative, rather than toxic, effects. However, selective toxic effects on the clonogenic cells by WT1 cannot be completely ruled out, since these could be concealed within the whole cell population.
Previous results have indicated a differentiation-inhibitory role for WT1 in some hematopoietic cell lines, 18, 30, 31 while maturation of other cell lines was either not affected or enhanced by the expression of WT1. 32, 41, 45 Our results give no support for an impaired differentiation of human hematopoietic progenitors due to forced expression of WT1. However, this might be the result of selection against cells expressing high levels of WT1 (not dividing during culture). Antiproliferative effects might therefore conceal a block of differentiation. Moreover, other aspects of maturation, not revealed by the surface markers analyzed, may be affected, similar to the partial block of differentiation in U937 cells constitutively over-expressing WT1. 18, 30, 31 Ellisen et al 41 reported WT1-mediated enhancement of myeloid differentiation of more mature hematopoietic progenitor cells. In contrast, we did not observe any increased differentiation induction in WT1-transduced cells compared to cells transduced with control vector. The discrepancy between the differentiation data of their and our report can probably be explained by the use of different cytokine combinations for the induction of differentiation. Our cytokine combination strongly drives cells to myeloid or erythroid differentiation, and a possible positive effect of WT1 on differentiation may not be detected.
Recently, constitutive expression of non-spliced human WT1 in murine progenitor cells was reported; 34 during culture with G-CSF alone, proliferation of WT1-transduced cells was promoted, while clonogenic growth was unaffected under all other culture conditions tested. 34 Our present results from murine cells, showing no significant effects on clonogenic growth of bone marrow cells, are consistent with those of Tsuboi et al, suggesting a different function or lower susceptibility for WT1 in murine cells, as compared to human progenitor cells. The reasons for the discrepancy between the response among human and murine cells are unclear, but it may be that different target cell populations are used in the two studies, non-enriched bone marrow cells in the murine experiments as compared to CD34
+ selected cord blood cells in the human studies. The use of human highly enriched CD34
+ progenitor cells in the present investigation makes it unlikely that the observed effects of WT1 expression are indirect, ie mediated by transduced accessory cells present in the cell population. Moreover, although the conservation of the amino acid sequence between human and murine WT1 is very high, 46 it should be noted that the use of human WT1 in murine cells could produce misleading results.
The molecular mechanisms behind the WT1-induced retardation of the proliferation rate of hematopoietic progenitors remain unknown, but it is plausible that they involve transcription of genes involved in the regulation of the cell cycle. In support of this, it has been shown that WT1 transiently transfected to the monoblastic cell line U937 mediated growth arrest, which was associated with induction of the cyclin-dependent kinase inhibitor p21 CIP1 . 41 In non-hematopoietic cells other transcriptional targets for WT1 are also suggested as mediators of growth arrest. These include the receptors for insuline-like growth factor I and 1,25-dihydroxyvitamin D3 and the protooncogene bcl-2. [47] [48] [49] [50] Hypothetically, these genes could also be involved in the regulation of proliferation of hematopoietic cells. Interestingly, the gene for ornithine decarboxylase, expression of which is necessary for quiescent cells to enter the cell cycle (reviewed in Ref. 51 ) is reported to be negatively regulated by WT1. 52 If WT1 blocks the proliferation of progenitor cells, how then can WT1 contribute to leukemogenesis? The answer could be that the transformation process, including several oncogenic events, includes a selection against the anti-proliferative effects of WT1 making it possible for WT1 to co-operate with certain oncogene products and to interfere with differentiation. The observed interference with the maturation of certain myeloid cell lines, in which anti-proliferative effects not are detected, 18, 30, 31 is consistent with this notion. In conclusion, the present data demonstrate that forced expression of WT1 in highly enriched human hematopoietic progenitor cells confers a potent inhibition on proliferation during differentiation. Our results shed new light on the enigmatic role of WT1 in hematopoiesis and leukemogenesis.
